These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 22023666)

  • 1. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
    Lowe G; Costabile RA
    J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
    Scranton RE; Goldstein I; Stecher VJ
    J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
    Kamenov ZA
    J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
    Herlemann A; Gratzke C; Andersson KE; Sievert KD
    Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase type 5 inhibitor abuse: a critical review.
    Lowe G; Costabile R
    Curr Drug Abuse Rev; 2011 Jun; 4(2):87-94. PubMed ID: 21696344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
    Shindel AW
    J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical monograph for drug formulary review: erectile dysfunction agents.
    Campbell HE
    J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
    Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
    [No Abstract]   [Full Text] [Related]  

  • 14. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
    Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
    J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
    Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
    J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.